Single low dose cyclophosphamide

DRUG6 trials

Sponsors

Merck KGaA, Darmstadt, Germany, EMD Serono

Conditions

Carcinoma, Non-Small-Cell LungLung NeoplasmsMultiple MyelomaNon-Small Cell Lung CancerNon-small Cell Lung Cancer

Phase 1

Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

CompletedNCT00960115

Merck KGaA, Darmstadt, GermanyNon-small Cell Lung Cancer

Start: 2008-12-31End: 2015-06-30Updated: 2015-10-21

Phase 2

Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease

CompletedNCT00157196

Merck KGaA, Darmstadt, GermanyCarcinoma, Non-Small-Cell Lung, Lung Neoplasms

Start: 2005-04-30End: 2012-04-30Updated: 2015-08-18

Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)

CompletedNCT00157209

Merck KGaA, Darmstadt, GermanyCarcinoma, Non-Small-Cell Lung, Lung Neoplasms

Start: 2000-08-31End: 2012-07-31Updated: 2015-11-18

Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy

CompletedNCT01094548

Merck KGaA, Darmstadt, GermanyMultiple Myeloma

Start: 2008-01-31End: 2012-03-31Updated: 2016-02-22

Phase 3

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

CompletedNCT00409188

EMD SeronoNon-small Cell Lung Cancer

Start: 2007-01-31End: 2015-04-30Updated: 2015-11-20

Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population

TerminatedNCT01015443

Merck KGaA, Darmstadt, GermanyNon-Small Cell Lung Cancer

Start: 2009-12-31End: 2015-06-30Updated: 2016-10-26

Related Papers

Phase I/II study of tecemotide cancer immunotherapy for Japanese patients with unresectable stage III non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2015-05-205 citations

Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.

2015-02-2673 citations

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

2013-12-09391 citations

Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer.

2013-04-1162 citations

INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer.

2011-10-0760 citations